Related Experiment Video
Updated: Jul 9, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Cardiovascular risk in hemodialysis patients: a mechanistic approach
1University of Western Ontario Division of Nephrology, University Hospital, London Health Sciences Centre, London, Ontario, Canada. andrew.house@lhsc.on.ca
Insights
A new formula quantifies cardiovascular risk in hemodialysis patients, considering chronic kidney disease and dialysis effects. It highlights potential benefits of new technologies and drug therapies in managing this elevated risk.
Area of Science:
- Nephrology
- Cardiology
- Public Health
Background:
- Cardiovascular disease is a major concern for hemodialysis patients.
- Existing risk assessments may not fully capture the unique factors affecting this population.
Purpose of the Study:
- To propose a novel formula quantifying the excess cardiovascular risk in hemodialysis patients.
- To identify and review key factors contributing to cardiovascular risk in this group.
Main Methods:
- Development of a new formula: CVR(HD) = CVR(B) X f(([CKD+HD]/[HD(tech)+Dr])+X).
- Review of epidemiological, pathophysiological, and therapeutic implications of formula components.
- Identification of modifiable risk factors.
Main Results:
- The formula integrates baseline risk, chronic kidney disease (CKD), hemodialysis (HD) process risks, technological benefits (HD(tech)), and drug therapy benefits (Dr).
- CKD and HD significantly amplify baseline cardiovascular risk.
- New hemodialysis technologies and drug therapies show potential for risk mitigation.
Conclusions:
- The proposed formula provides a framework for understanding and quantifying cardiovascular risk in hemodialysis patients.
- Strategies focusing on "cardioprotective dialysis" and optimized drug treatment are crucial.
- Further research into unknown factors (X) is warranted.
Abstract:
A new formula is proposed to express the excess burden of cardiovascular risk faced by hemodialysis patients as a function of various inherent, acquired and potentially modifiable factors. The proposed equation CVR(HD) = CVR(B) X f(([CKD+HD]/[HD(tech)+Dr])+X) includes the terms: CVR(HD) (cardiovascular risk in hemodialysis patients); CVR(B) (baseline cardiovascular risk); CKD (risk associated with chronic kidney disease); HD (risks associated with the process of hemodialysis); HD(tech) (benefits of new hemodialysis technologies); Dr (benefits of drug therapies) and X (unknown or putative factors influencing cardiovascular morbidity). We review the various factors included in this proposed formula, touching upon the epidemiology, pathophysiology and therapeutic implications, including possible strategies to modify risk. As is apparent from the formula, CKD and HD in particular act as risk multipliers in augmenting or amplifying the baseline cardiovascular risk, while new hemodialysis technologies may provide an opportunity for "cardioprotective dialysis". Drug treatment may serve to mitigate some of the risk unique to this population.
Related Concept Videos
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis
Heart Failure Drugs: Diuretics
